bluebird bio, Inc.
BLUE · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0.5% | 263% | -34.1% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 68.4% | 40.8% | -11% | -79.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -19.8% | -23.4% | -374.5% | -368.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -75.1% | -74.5% | -573% | -505.5% |
| EPS Diluted | -2.98 | -0.45 | -0.95 | -1.27 |
| % Growth | -562.2% | 52.6% | 25.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |